ACLX
HealthcareArcellx, Inc. · Biotechnology · $7B
What is Arcellx, Inc.?
Arcellx, Inc. is a clinical-stage biotechnology company developing next-generation immunotherapies for patients with cancer and other serious diseases. Its pipeline centers on novel CAR-T cell and SparX protein technologies aimed at difficult-to-treat blood cancers.
Arcellx generates no product revenue yet — it is a pre-commercial biotech advancing a pipeline of cell therapies through clinical trials. Its lead program, CART-ddBCMA, uses a differentiated domain-specific CAR construct to target BCMA, a protein expressed in multiple myeloma cells. Beyond that lead asset, the company is developing combination immunotherapeutic approaches and programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Revenue, if any, currently comes from collaboration agreements rather than product sales.
Arcellx was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
- CART-ddBCMA — lead CAR-T candidate for relapsed or refractory multiple myeloma
- ACLX-001 — ARC-T cell and bi-valent SparX protein combination targeting BCMA
- ACLX-002 and ACLX-003 — programs targeting relapsed or refractory AML and MDS
- Solid tumor pipeline programs leveraging the ddCAR platform
Is ACLX a Good Stock to Buy?
UQS Score rates ACLX as Poor overall, reflecting the early-stage nature and financial profile typical of clinical-stage biotechs.
The standout pillar for Arcellx is Risk, which scores Strong — an unusual result for a pre-revenue biotech and likely reflects a relatively clean balance sheet and manageable near-term liabilities. This provides some runway cushion as the pipeline matures.
Quality and Moat both register as Weak, consistent with a company that has no commercial products and no established competitive position yet. Valuation is Elevated, meaning the market is pricing in significant future success that has yet to be demonstrated clinically.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ACLX pay dividends?
No — Arcellx, Inc. does not currently pay a dividend.
Arcellx does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward funding clinical trials, research operations, and pipeline development. Income-focused investors should look elsewhere; ACLX is a pure capital-appreciation thesis tied to pipeline progress.
When does ACLX report earnings?
Arcellx reports financial results on a quarterly cadence, as is standard for US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results center on cash burn, operating expenses, and any collaboration revenue rather than product sales or profitability. Pipeline milestones and clinical data readouts tend to move the stock more than earnings beats or misses.
For the most recent quarter's results and cash position, visit Arcellx's investor relations page directly.
ACLX Price History
+500.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Arcellx, Inc.?
Based on Arcellx, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ACLX Long-term Outlook
Arcellx's Growth pillar is rated Neutral, suggesting the market sees a plausible but uncertain path to value creation. The strong Risk rating provides some confidence that the company is not in immediate financial distress. However, the Elevated Valuation pillar indicates the current share price already embeds optimistic assumptions about clinical and regulatory outcomes that remain unproven.
Growth drivers
- Advancement of CART-ddBCMA through later-stage clinical trials and potential regulatory milestones
- Expansion of the SparX platform into AML, MDS, and solid tumor indications
- Potential partnership or licensing deals that could validate the ddCAR technology
Key risks
- Clinical trial failure or disappointing efficacy and safety data across any program
- Elevated valuation leaves limited margin of safety if pipeline progress slows
- Ongoing cash consumption with no product revenue to offset operating expenses
ACLX vs Peers
Arcellx operates in a competitive clinical-stage biotech landscape alongside other companies developing novel therapies for hematologic and other cancers.
Protagonist focuses on peptide-based medicines for blood disorders and inflammatory diseases, using a distinct mechanism from Arcellx's CAR-T platform.
Belite Bio targets retinal diseases and metabolic conditions, representing a different therapeutic area but a similar pre-commercial development stage.
Kymera pursues targeted protein degradation across oncology and immunology, offering a mechanistically different approach to some of the same disease areas Arcellx targets.
Frequently Asked Questions
What does Arcellx do?
Arcellx is a clinical-stage biotechnology company developing immunotherapies for cancer. Its core technology is a differentiated CAR-T cell platform called ddCAR, with the lead program targeting multiple myeloma and additional programs aimed at acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. The company has no approved products on the market yet.
Does ACLX pay dividends?
No, Arcellx does not pay a dividend. Pre-revenue biotechs at the clinical stage typically reinvest all available capital into research and clinical operations. Investors in ACLX are betting on pipeline success rather than income generation.
When does ACLX report earnings?
Arcellx reports on a standard quarterly schedule. Because it is pre-commercial, the most watched figures are cash runway and operating expenses rather than revenue or profit. Check Arcellx's investor relations page for the latest quarterly report and scheduled update dates.
Is ACLX a good stock to buy?
UQS Score rates ACLX as Poor overall, driven by Weak Quality and Moat scores and an Elevated Valuation. The Strong Risk pillar is a relative bright spot. Whether ACLX fits a portfolio depends on an investor's risk tolerance for clinical-stage biotech exposure. View the full pillar breakdown on UQS Pro for a deeper picture.
Is ACLX overvalued?
The UQS Valuation pillar for ACLX is rated Elevated, meaning the current market price appears to reflect optimistic assumptions about future clinical and commercial success. For a pre-revenue company, valuation is inherently speculative and tied closely to pipeline milestones rather than current financials.
How does ACLX compare to its competitors?
Arcellx competes in the broader clinical-stage biotech space alongside companies like Protagonist Therapeutics, Belite Bio, and Kymera Therapeutics. Each pursues different mechanisms and disease areas. UQS Pro provides side-by-side pillar comparisons so you can evaluate how ACLX's Quality, Growth, Moat, Risk, and Valuation stack up against peers.
What is ACLX's market cap bracket?
Arcellx is currently classified as a mid-cap company. This places it above the micro- and small-cap tiers common among early clinical-stage biotechs, suggesting the market has assigned meaningful value to its pipeline — though that valuation remains speculative pending clinical data.
Who founded Arcellx?
Arcellx was originally incorporated as Encarta Therapeutics, Inc. in 2014 before rebranding to Arcellx in January 2016. Founding and leadership details are publicly available through the company's official disclosures and SEC filings on its investor relations page.
Is ACLX a long-term quality investment?
As a long-term quality indicator, UQS rates ACLX as Poor overall, with Weak scores in Quality and Moat. Long-term quality investing typically favors companies with durable competitive advantages and consistent financial performance — attributes that clinical-stage biotechs like Arcellx have yet to establish. The pipeline could change that picture if key trials succeed.
What is the main competitive advantage of Arcellx?
Arcellx's potential differentiation lies in its proprietary ddCAR platform, which uses a domain-specific design intended to improve the precision and safety profile of CAR-T cell therapies. Whether this translates into a durable moat depends on clinical outcomes and regulatory approvals that are still pending.
What sector does ACLX belong to?
Arcellx operates in the Healthcare sector, specifically within clinical-stage biotechnology. It focuses on cell therapy and immunotherapy — a high-risk, high-potential subsegment of biotech where outcomes are binary and timelines are long. Explore other [healthcare stocks scored by UQS](/sector/healthcare) for broader context.
Is ACLX a growth stock or value stock?
ACLX carries a Neutral Growth pillar rating and an Elevated Valuation pillar rating. That combination suggests the market is paying a premium for growth potential that has not yet materialized in financial results. It is best characterized as a speculative growth-oriented name rather than a value play.
Unlock Full ACLX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare ACLX side-by-side with sector peers
- ✓See the complete risk and valuation breakdown
- ✓Get the full analyst-style quality assessment
- ✓Track pipeline-stage biotech scores in one place
Pro Analysis
ACLX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 26.8 | 1.3 | 27.0 | 36.9 | 82.4 | 0.0 | +0.3 |
| May 10, 2026 | 26.5 | 0.0 | 27.0 | 36.9 | 82.4 | 0.0 | -0.3 |
| Apr 22, 2026 | 26.8 | 1.3 | 27.0 | 36.9 | 82.4 | 0.0 | -1.8 |
| Apr 2, 2026 | 28.6 | 1.3 | 27.0 | 46.2 | 82.4 | 0.0 | — |
ACLX — Pillar Breakdown
Quality
— 1.3/100 (25%)Arcellx, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.9/100 (20%)Arcellx, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Arcellx, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Arcellx, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 27/100 (25%)Arcellx, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ACLX.
Score Composition
Financial Data
More Stock Analysis
How is the ACLX UQS Score Calculated?
The UQS (Unified Quality Score) for Arcellx, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Arcellx, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Arcellx, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.